Quick Answer
Stoke Therapeutics, Inc. reported Stockholders Equity of $352.46 million for the year ending 2025.
- Stoke Therapeutics, Inc. showed an increase of +53.9% in Stockholders Equity from 2024 to 2025.
- This data is from Stoke Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $12.22 million | Q2 2018: $9.29 million | Q3 2018: $19.39 million | Q1 2019: $99.58 million | Q2 2019: $241.54 million | Q3 2019: $233.68 million | Q1 2020: $214.34 million | Q2 2020: $203.40 million | Q3 2020: $192.54 million | Q1 2021: $272.47 million | Q2 2021: $255.07 million | Q3 2021: $237.51 million | Q1 2022: $239.98 million | Q2 2022: $224.32 million | Q3 2022: $204.14 million | Q1 2023: $213.82 million | Q2 2023: $190.20 million | Q3 2023: $173.00 million | Q1 2024: $140.34 million | Q2 2024: $242.71 million | Q3 2024: $232.11 million | Q1 2025: $350.07 million | Q2 2025: $334.94 million | Q3 2025: $308.11 million.
- Over the full 9 years of available data (2017 to 2025), Stoke Therapeutics, Inc.'s Stockholders Equity has grown by 27,380.0%.
- Historical annual values: Fiscal year 2025: $352.46 million | Fiscal year 2024: $229.02 million | Fiscal year 2023: $159.57 million | Fiscal year 2022: $184.85 million | Fiscal year 2021: $217.78 million | Fiscal year 2020: $286.08 million | Fiscal year 2019: $224.43 million | Fiscal year 2018: $105.07 million | Fiscal year 2017: -$1.29 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: